Autem Therapeutics

A clinic visit, a calibrated signal, and a patient who keeps the rest of their day

Picture a treatment room with no IV pole, no warning labels about toxicity, no cold-storage unit humming in the corner. A patient sits down. A device delivers a low-level, amplitude-modulated electromagnetic signal tuned to their tumor. Then they go home. This is the room Autem Therapeutics is trying to build at scale - and the one cancer medicine has rarely offered.

Autem Therapeutics is a bioelectric oncology company headquartered in Hanover, New Hampshire - a town better known for Dartmouth than drug pipelines. Its product, AutEMsys, is a non-invasive, non-toxic system that treats solid tumors with electromagnetic frequencies rather than molecules. The lead target is hepatocellular carcinoma, the most common form of liver cancer and one of the harder cancers to treat well.

Cancer care that works often asks the patient to suffer for it

Surgery, chemotherapy, radiation - the standard arsenal is effective and brutal in roughly equal measure. For liver cancer, the picture is harder still: many patients are diagnosed late, tumors recur, and the treatments that exist can be as taxing as the disease. The side effects aren't a footnote. They're the reason a lot of people stop treatment.

There's a second problem, quieter but just as stubborn. Most advanced cancer therapy assumes a wealthy hospital: cold-chain logistics, infusion suites, specialist staff. That assumption quietly writes off enormous parts of the world. A drug that needs refrigeration and a sterile IV line is a drug that doesn't travel.

Autem's founders looked at both problems and saw the same root: the tools were built to attack cancer chemically, and chemistry is heavy, toxic, and hard to ship. What if the lever was physical instead?

An oncologist who got tired of the menu

The company traces back to 2017 and Frederico Costa, a medical oncologist who had spent his career inside the chemical paradigm and wanted a different lever. The bet he and the team made rests on the Warburg effect - the long-observed fact that cancer cells run an unusual, energy-hungry metabolism that sets them apart from healthy neighbors. If cancer cells are electrophysiologically out of sync, the reasoning goes, perhaps the right electromagnetic frequencies can nudge them back toward balance, or starve their abnormal rhythm.

It's a physics answer to a biology question. That's exactly why it needed an unusual team. Michael Choukas joined as co-founder and stepped in as CEO when the company raised its Series A, pairing Costa's clinical science with operating leadership.

AutEMsys, explained without the hand-waving

AutEMsys delivers personalized, low-level, amplitude-modulated electromagnetic frequencies to a patient's whole system, on a schedule of two- or four-week intervals. The signals are meant to be tumor-specific rather than a single generic broadcast - the device is doing calibration, not just emission.

The engineering choices say a lot about who Autem is designing for. One unit can serve up to 40 patients a month. It needs no refrigeration. That isn't a spec-sheet flourish; it's the whole accessibility thesis turned into hardware. A device that runs without a cold chain is a device that can sit in a clinic far from a major cancer center.

Make cancer treatment safe, effective, and reachable

Most mission statements pick one virtue and lean on it. Autem's stacks three that usually trade off against each other: safe, effective, accessible. The toxic treatments tend to be the powerful ones. The accessible treatments tend to be the cheap, weak ones. Autem's wager is that a physical, hardware-based therapy can refuse that trade - delivering real anti-tumor effect without the toxicity, in a form that can travel past the walls of an elite hospital.

That ambition is why the company keeps pairing its science claims with logistics claims. No refrigeration. Forty patients a month. Two- or four-week intervals. These aren't marketing lines - they're the difference between a therapy that helps a few thousand insured patients and one that could reach people the current system never planned to serve.

Back to that quiet treatment room

Autem still has the hardest mile ahead: the controlled clinical trials that turn a Breakthrough designation into approved medicine. Bioelectric oncology is a young field, and skepticism is the correct default - frequencies are easy to promise and hard to prove. The IDE-gated trials in HCC and glioblastoma are where the thesis either holds or doesn't.

But return to the room from the opening. No IV pole. No toxicity warnings. No humming fridge. A patient sits, receives a tuned signal, and reclaims the rest of their day - and, if the data holds, gets that day in a clinic that could never have run a chemo suite. That room used to be a fantasy. Autem Therapeutics is trying to make it a floor plan.